ViewRay, Inc. (NASDAQ:VRAY – Get Rating) Director Susan C. Schnabel purchased 10,000 shares of the business’s stock in a transaction dated Monday, May 9th. The stock was bought at an average cost of $2.41 per share, with a total value of $24,100.00. Following the completion of the acquisition, the director now owns 73,279 shares of the company’s stock, valued at $176,602.39. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website.
ViewRay stock opened at $3.30 on Friday. The firm has a market capitalization of $595.51 million, a P/E ratio of -5.16 and a beta of 1.12. The stock has a fifty day moving average price of $3.46 and a 200 day moving average price of $4.53. ViewRay, Inc. has a 52 week low of $2.39 and a 52 week high of $8.25. The company has a current ratio of 3.17, a quick ratio of 3.33 and a debt-to-equity ratio of 0.33.
ViewRay (NASDAQ:VRAY – Get Rating) last posted its quarterly earnings results on Thursday, May 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. ViewRay had a negative return on equity of 76.00% and a negative net margin of 148.47%. The firm had revenue of $18.88 million during the quarter, compared to the consensus estimate of $15.62 million. During the same quarter in the previous year, the business earned ($0.17) earnings per share. The firm’s quarterly revenue was up 21.6% compared to the same quarter last year. As a group, equities analysts predict that ViewRay, Inc. will post -0.61 EPS for the current year.
A number of equities analysts have recently weighed in on the company. Zacks Investment Research raised ViewRay from a “hold” rating to a “buy” rating and set a $2.75 price target for the company in a report on Wednesday. Stifel Nicolaus initiated coverage on ViewRay in a report on Tuesday, January 25th. They issued a “buy” rating and a $7.00 price target for the company. StockNews.com initiated coverage on ViewRay in a research note on Thursday, March 31st. They issued a “sell” rating for the company. Finally, Piper Sandler dropped their target price on ViewRay from $9.00 to $7.00 in a research note on Friday, May 6th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $5.94.
About ViewRay (Get Rating)
ViewRay, Inc designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, France, Taiwan, the United Kingdom, and internationally. The company provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns.
- Get a free copy of the StockNews.com research report on ViewRay (VRAY)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for ViewRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ViewRay and related companies with MarketBeat.com's FREE daily email newsletter.